ACRO AI/ML Committee Releases Principles for Responsible AI

ACRO today announced the release of ACRO’s Principles for Responsible AI. Drafted by a team of CRO and technology subject matter experts, the ACRO Principles articulate an approach to the use of AI in drug development that emphasizes thoughtful design, transparency, and accountability in the context of clinical research.

“Just as ChatGPT has ushered in a new era for AI, ACRO member companies recognize its enormous potential to improve the design, conduct and analysis of clinical trials,” stated Stephen Pyke, DIC, Chief Clinical Data & Digital Officer for Parexel and chair of the ACRO AI/ML Committee. “As in other fields, however, we recognize the potential harms that can arise with the use of such tools and will embrace a responsible approach that will accelerate the delivery of new medicines while respecting the needs and expectations of our most important stakeholder — the patient.”

Guided by frameworks for using artificial intelligence systems developed by the National Institute for Standards and Technologies (NIST) and other bodies, ACRO’s Principles for Responsible AI articulate 10 recommendations that organizations can consider as they develop and use AI technologies.

Read ACRO’s Principles for Responsible AI.

Scroll to Top